Nature Cancer

Article	Citations
Untangling the threads of immunotherapy research	649
Enhancing childhood cancer targetability	459
Shooting for multiplexed pathology with Orion	450
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	444
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	367
A low-coverage liquid biopsy for lung cancer	361
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	334
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	296
Breaking frontiers with multidisciplinary cancer research	276
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	273
A macrophage-activated abscopal effect	267
An oncolytic circular RNA therapy	245
Considering molecular alterations as pan-cancer tissue-agnostic targets	225
Gut decisions in CAR T cell therapy	221
PARP11 interfer(on)es with CAR T cell efficacy	205
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	161
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	160
MALAT1 protects dormant tumor cells from immune elimination	157
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	152
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	149
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	140
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	137
The cGAS–STING pathway and cancer	127
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	125
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	125

DePICting T cell–APC crosstalk in cancer	123
Beating cancer one carbon at a time	123
Expanding the options for KRAS inhibition	121
Palmitate oxidation drives a pro-metastatic post-translational modification	118
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	118
Stress granules shape metabolic reprogramming and drug resistance	116
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	112
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	112
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	110
The importance of being generous	102
Bone marrow progenitor-like cells against leukemia cure	99
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	98
Shaping the microenvironment in peritoneal metastases	98
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	97
Advancing therapeutics in small-cell lung cancer	95
Determinants of resistance and response to melanoma therapy	95
Impact of context-dependent autophagy states on tumor progression	95
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	94
Sarcoma ecotypes determine immunotherapy benefit	93
Innate immunity drives epithelial cell plasticity during prostate tumor formation	93
Antibody avidity meets multiple myeloma	92
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	92
Thriving in diverse ecosystems	91
Inflammation meets translation in AML	91
Evolving landscape of nasopharyngeal carcinoma therapy	91
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	90
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	90
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	89
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	88
Key insights from ESMO Congress 2025	83
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	83
Cycling back to folate metabolism in cancer	78
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	78
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	77
A comeback for checkpoint inhibition in multiple myeloma	76
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	76
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	76
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	75
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	74
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	73
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	73
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	73
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	72
Radioligand cancer therapy comes to the fore	72
Radiation sparks a dark side in neutrophils	72
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	72
Multimodal data integration improves immunotherapy response prediction	71
Dual inhibition of EGFR and PI3K with a single drug	71
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	70
Bispecific antibodies seek out colon cancer stem cells	70

First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	69
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	68
How AI agents will change cancer research and oncology	67
Building a translational cancer dependency map for The Cancer Genome Atlas	66
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	66
Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	66
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	65
Immunotargeting of a recurrent AML-specific neoantigen	65
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	64
AKTing on XPO1 inhibition in AML	63
Selective targeting of malignant T cells	63
Highlights from the 2025 ASCO Annual Meeting	63
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	63
Macrophage mitochondrial fission improves cancer cell phagocytosis induced by therapeutic antibodies and is impaired by glutamine competition	62
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	62
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	61
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	61
Bispecific chimeric T cell receptors tackle tumor heterogeneity	60
Advances in antibody-based therapy in oncology	59
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	59
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	59
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	59
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	59
LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer	59
Anything to declare?	58
The tumor microenvironment’s role in the response to immune checkpoint blockade	58
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	58
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	58
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	57
Epigenetic plasticity in PDAC	57
Neoadjuvant immunotherapy marks a new era in oncology	57
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	56
Metabolic symbiosis in pancreatic cancer	56
Myeloma evades T cell-engaging therapies	56
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	55
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	55
An unexpected career in cancer metabolism	55
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	54
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	54
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy	54
SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes	52
There are gremlins in prostate cancer	52
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	52
In vivo macrophage engineering for renal cancer therapy	51
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	51
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	51
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	51
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	50
Clinical and translational attributes of immune-related adverse events	50
p53 at the crossroads of tumor immunity	50
Ricolinostat is not a highly selective HDAC6 inhibitor	50
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	49
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	49
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	49
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	49
Circumventing the roadblocks to targeting EGFR-driven cancers	49
Breaking the performance ceiling for neoantigen immunogenicity prediction	47
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	47
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	47
Masking T cell engagers mitigates on-target off-tumor activity	47
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	46
A new sophistication for breast cancer PDXs	46
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	46
Understanding the biology of lung cancer brain metastases	46
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	45
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	43
CAR T cell therapy: looking back and looking forward	42
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	42
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	41
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	41
CD8+ T cell killing of MHC class I–deficient tumors	41
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	41
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	41
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	40
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	40
The meaning of impact	40
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	40
Communicating with respect	40
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	40
Artificial intelligence for prostate cancer diagnostics	39

Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	39
Near-infrared optogenetic engineering of bacteria for cancer therapy	37
Leveraging the potential for deintensification in cancer care	37
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	37
CD4+ CAR T cells — more than helpers	37
Leveraging translational insights toward precision medicine approaches for brain metastases	37
Therapeutic targeting of the mevalonate–geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer	36
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	36
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	36
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	36
Commensal metabolite boosts chemotherapy	35
Acute lymphoblastic leukemia displays a distinct highly methylated genome	35
Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	35
Radiopharma pipeline builds ahead of key data	35
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	35
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	34
Disparities, aging and childhood cancer	34
The aging lung reawakens dormant tumor cells	34
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	33
Fibrotic tumors tune metabolism for immune evasion	33
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	33
Targeting HIF-1 to treat AML	32
Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence	32
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	32
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	32
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	32
The growing threat of cyberwarfare in cancer healthcare	31
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	31
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	31
The landscape of T cell antigens for cancer immunotherapy	31
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	31
Remodeling cyclophilin A to target KRAS	30
CAR T cell therapy for multiple myeloma	30
Checkpoint blockade regulates T cell fate by supporting co-stimulation	30
Not a generative AI–generated Editorial	30
Publisher Correction: Cancer’s new normal	30
Phenotypic diversity of T cells in human primary and metastatic brain tumors revealed by multiomic interrogation	29
Resistance is futile with fourth-generation EGFR inhibitors	29
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer	29
The two sides of the γδ T cell coin	29
Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment	29
Bicarbonate transport as a vulnerability in pancreatic cancer	29
Checking immunotoxicity risks of checkpoint blockade	29
LncRNA Malat1 suppresses pyroptosis and T cell-mediated killing of incipient metastatic cells	28
T cells lead the charge against solid tumors	28
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect	27
Tumor-specific cholinergic CD4+ T lymphocytes guide immunosurveillance of hepatocellular carcinoma	27
Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	27
Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia	27
The editors’ point of view	26
Neoadjuvant chemotherapy enriches for drug-tolerant persisters in PDAC	26
Exploiting HLA-DR mismatches for CAR therapy in acute myeloid leukemia	25
The craft (and art) of scientific writing	25
Mini colons to study cancer ex vivo	25
A roadmap of therapeutic strategies for patients with multiple myeloma	25
Neutrophils determine immunotherapy success	24
Understanding inequities in precision oncology diagnostics	24
Characterization of cis-regulatory elements and functional variants in colorectal cancer using epigenomics and CRISPRi screenings	24
Inferring early genetic progression in cancers with unobtainable premalignant disease	24
Keeping brain metastases dormant	24
SIGLEC9 tips the myeloid balance in glioblastoma	24
An in vitro-transcribed circular RNA targets the mitochondrial inner membrane cardiolipin to ablate EIF4G2+/PTBP1+ pan-adenocarcinoma	23
Blocking methionine catabolism induces senescence and confers vulnerability to GSK3 inhibition in liver cancer	23
Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer	23
Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology	22
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy	22
A designer peptide against the EAG2–Kvβ2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma	22
Targeting TAK1 in microglia to treat CAR T cell neurotoxicity	22
European cancer research requires renewed urgency	22
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo	22
Hallmarks of artificial intelligence contributions to precision oncology	22
SOS1 inhibitor combinations overcome KRAS inhibitor resistance	21
Publisher Correction: TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	21
Mind the GAP(43) for mitochondria transfer to glioblastomas	21
Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule	21
A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway	20
Glutamine analogs for pancreatic cancer therapy	20
Selective deficiency of mitochondrial respiratory complex I subunits Ndufs4/6 causes tumor immunogenicity	20
Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities	20
LORIS robustly predicts patient outcomes with immune checkpoint blockade therapy using common clinical, pathologic and genomic features	20
Starfish infers signatures of complex genomic rearrangements across human cancers	20
Mesenchymal and adrenergic cell lineage states in neuroblastoma possess distinct immunogenic phenotypes	20
CD8+ T cells maintain killing of MHC-I-negative tumor cells through the NKG2D–NKG2DL axis	19
KDM6B-mediated reprogramming of myeloid cells regulates the response to immunotherapy	19
Proteogenomic analysis of human pancreatic ductal adenocarcinoma	19
Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity	19
An antibody–toxin conjugate enhances innate immune cell responses in tumors	19
Inhibition of ADAM9 promotes the selective degradation of KRAS and sensitizes pancreatic cancers to chemotherapy	19
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical features	19
Palmitoylation regulates ferroptosis and anti-tumor immunity	19
The expanding success of T cell-engaging bispecific antibodies	18
The never-abating excitement for targeted therapies	18
Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer	18
Felix Feng (1975–2024)	18
The 2022 generation	18